Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996672 | 0.87 | GAA (0.44) | GAAARALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20766672 | 0.82 | GAA (0.47) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1976657 | 0.81 | GAA (0.42) | GAAARALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31305200 | 0.81 | HPGD (0.46) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2427915 | 0.81 | GAA (0.49) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2964001 | 0.80 | AR (0.46) | AR | |
| SCHEMBL1973358 | 0.79 | GAA (0.44) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4923169 | 0.79 | ALDH1A1 (0.47) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4085699 | 0.78 | KDM4E (0.40) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23089679 | 0.78 | PTGS2 (0.51) | GAAALDH1A1LMNAABL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732480-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732480-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7696241-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696241-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1722790-A4 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| EP-1722790-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | Bristol-Myers Squibb Company (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005086735-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | AR, NR5A1, ESRRA | GAA 3661/4885AR 1/4885ALDH1A1 1595/4885 |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | AR, NR5A1, ESRRA | GAA 3365/4885AR 1/4885ALDH1A1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.